JPM2022: Belief Biomed produces gene therapy in-house, Regor delivers fast drug discovery
Elise Mak · 01/13/2022
Chinese biotech startups Belief Biomed is one of the few gene therapy players with in-house manufacturing capabilities, and Regor is able to deliver one preclinical candidate in 10 months with its rCARD platform.
JPM2022: BeiGene and Zai Lab tout R&D plans, Legend ready for launch
Elise Mak · 01/12/2022
BeiGene aims 10 new molecules in clinic each year from 2024, Zai Lab targets 15+ marketed products across 35+ indications by 2025, RemeGen serves as Seagen’s ADC partner in China, and Legend gets ready for BCMA CAR-T launch.
JPM2022: Sinovac’s revenue soars 161 times, CanSino tests inhaled COVID vaccine
Elise Mak · 01/11/2022
Sinovac’s revenue soared 161 times thanks to its COVID-19 vaccine and CanSino is looking into an inhalable vaccine as booster, executives revealed at the 40th Annual J.P. Morgan Health Care Conference on Monday.
Over 30 Chinese drugmakers to appear at J.P. Morgan Health Care Conference
Elise Mak · 01/10/2022
This year, 33 mainland Chinese companies, ranging from drugmakers to CROs, will be addressing to investors and analysts at biotech's biggest annual conference from Jan. 10 to Jan. 13, up from 22 last year.
Henlius plans for approval of its PD-1 lung cancer drug in China and abroad
Minhua Chu · 01/04/2022
Shanghai Henlius Biotech is beginning to see strong sales from its trastuzumab biosimilar and wants to take its PD-1 drug abroad.
Grand Pharma to bring targeted radiation therapy to HCC patients in China
Elise Mak · 12/24/2021
SIR-Spheres Y-90 resin microspheres have been used in selective internal radiation therapy in the U.S. for almost two decades. Now they have come to China to treat patients with unresectable liver cancer.
BeiGene looks to incubate startups for degenerative diseases
Elise Mak · 12/23/2021
BeiGene is now looking to support local startups to explore beyond oncology and autoimmune diseases. Its new innovation center in Guangzhou is set to foster a biotech ecosystem that it believes is long overdue.
Neukio CEO: Make cell therapy allogenic, accessible and effective in solid tumors
Elise Mak · 12/22/2021
After launching the first CAR-T therapy on China market, Richard Wang wants to stay on the R&D frontier to push for safer, more affordable and efficacious cell therapies for more patients with the iPSC-CAR-NK technology. To succeed, emphasizing innovation and CMC early on is key, he told PharmaDJ.
China’s first drug patent linkage case highlights loophole, lawyer warns
Elise Mak · 12/20/2021
Japanese pharma company Chugai has a patented drug in China. Two companies are seeking marketing approval for their generics. Now, Chugai can only sue one of them under the new patent linkage system.
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback:   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement